Preview

Медицинский алфавит

Расширенный поиск
Доступ открыт Открытый доступ  Доступ закрыт Доступ платный или только для Подписчиков

Проблема коморбидных инфекций у больных псориатическим артритом

https://doi.org/10.33667/2078-5631-2020-15-22-28

Полный текст:

Аннотация

В современной ревматологии проблема коморбидных инфекций (КИ) по-прежнему сохраняет актуальность. Это связано как с наличием аутоиммунного ревматического заболевания, так и с необходимостью применения препаратов с иммуносупрессивным действием. В статье рассмотрены некоторые вопросы КИ в рамках псориатического артрита (ПсА). Проанализирована частота КИ при лечении различными базисными противовоспалительными и генно-инженерными биологическими препаратами. Показана значимость превентивных мероприятий в отношении КИ при лечении Пс А.

Об авторах

Б. С. Белов
ФГБНУ «Научно-исследовательский институт ревматологии имени В.А. Насоновой»
Россия

Доктор медицинских наук, заведующий лабораторией изучения коморбидных инфекций и мониторинга безопасности лекарственной терапии

Москва



Н. В. Муравьева
ФГБНУ «Научно-исследовательский институт ревматологии имени В.А. Насоновой»
Россия

Кандидат медицинских наук, научный сотрудник лаборатории изучения коморбидных инфекций и мониторинга безопасности лекарственной терапии

Москва 



М. М. Баранова
ФГБНУ «Научно-исследовательский институт ревматологии имени В.А. Насоновой»
Россия

Клинический ординатор

Москва 



Т. В. Коротаева
ФГБНУ «Научно-исследовательский институт ревматологии имени В.А. Насоновой»
Россия

Доктор медицинских наук, заведующий лабораторией спондилоартритов и псориатического артрита

Москва



Список литературы

1. Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019 Jan; 80 (1): 251–265. e19. DOI: 10.1016/j.jaad.2018.06.027.

2. Mease PJ. Psoriatic Arthritis: update on pathophysiology, assessement and management. Ann Rheum Dis. 2011 Mar; 70 Suppl 1: i77–84. DOI: 10.1136/ard.2010.140582.

3. Wakkee M, de Vries E, van den Haak P, Nijsten T. Increased risk of infectious disease requiring hospitalization among patients with psoriasis: a population-based cohort. Jam Acad Dermatol. 2011 Dec; 65 (6): 1135–44. DOI: 10.1016/j.jaad.2010.08.036.

4. Kao LT, Lee CZ, Liu SP, et al. Psoriasis and the risk of pneumonia: a population-based study. PLoS One. 2014 Dec 26; 9 (12): e116077. DOI: 10.1371/journal.pone.0116077.

5. Hsu DY, Gordon K, Silverberg JI. Serious infections in hospitalized patients with psoriasis in the United States. J Am Acad Dermatol. 2016 Aug; 75 (2): 287–96. DOI: 10.1016/j.jaad.2016.04.00.

6. Takeshita J, Shin DB, Ogdie A, Gelfand JM. Risk of serious infection, opportunistic infection, and herpes zoster among patients with psoriasis in the United Kingdom. J Invest Dermatol. 2018; 138 (8): 1726–35.

7. Kalb RE, Fiorentino DF, Lebwohl MG, et al. Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). JAMA Dermatol. 2015 Sep; 151 (9): 961–9. DOI: 10.1001/jamadermatol.2015.0718.

8. Yiu ZZN, Smith CH, Ashcroft DM, et al. Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2018 Mar; 138 (3): 534–541. DOI: 10.1016/j.jid.2017.10.005.

9. Dávila-Seijo P, Dauden E, Descalzo MA, et al. Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry. J Invest Dermatol. 2017 Feb; 137 (2): 313–321. DOI: 10.1016/j.jid.2016.08.034.

10. Garcia-Doval I, Cohen AD, Cazzaniga S, et al. Risk of serious infections, cutaneous bacterial infections, and granulomatous infections in patients with psoriasis treated with anti-tumor necrosis factor agents versus classic therapies: Prospective meta-analysis of Psonetregistries. J Am Acad Dermatol. 2017 Feb; 76 (2): 299–308. e16. DOI: 10.1016/j.jaad.2016.07.039.

11. Dobry AS, Quesenberry CP, Ray GT, et al. Serious infections among a large cohort of subjects with systemically treated psoriasis. J Am Acad Dermatol. 2017 Nov; 77 (5): 838–844. DOI: 10.1016/j.jaad.2017.07.047.

12. Medina C, Carretero G, Ferrandiz C, et al. Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry. J Eur Acad Dermatol Venereol. 2015 May; 29 (5): 858–64. DOI: 10.1111/jdv.12688.

13. Saad AA, Ashcroft DM, Watson KD, et al. Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. Rheumatology. 2010; 49 (4): 697–705. DOI: 10.1093/rheumatology/kep423.

14. Mease P, Deodhar A, Fleischmann R. et al. Effect of certolizumabpegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure. RMD Open. 2015 Jun 25; 1 (1): e000119. DOI: 10.1136/rmdopen2015–000119.

15. Kavanaugh A, McInnes IB, Mease P, et al. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). Ann Rheum Dis. 2014; 73 (9): 1689–94. DOI: 10.1136/annrheumdis2013–204902.

16. Atzeni F, Sarzi-Puttini P, Sebastiani M, et al. Rate of serious infections in spondyloarthropathy patients treated with anti-tumour necrosis factor drugs: a survey from the Italian registry GISEA. Clin Exp Rheumatol. 2019 Jul-Aug; 37 (4): 649–655.

17. Quartuccio L, Zabotti A, Del Zotto S, et al. Risk of serious infection among patients receiving biologics for chronic inflammatory diseases: Usefulness of administrative data. J Adv Res. 2018 Sep 19; 15: 87–93. DOI: 10.1016/j.jare.2018.09.003.

18. Minozzi S, Bonovas S, Lytras T, et al. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf. 2016 Dec; 15 (sup1): 11–34. DOI: 10.1080/14740338.2016.1240783.

19. McKeage K. Ustekinumab: A Review of Its Use in Psoriatic Arthritis. Drugs (2014) 74: 1029–1039. DOI: 10.1007/s40265–014–0242–4.

20. Ritchlin CT, Stahle M, Poulin Y, et al. Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics.BMC Rheumatol. 2019 Nov 28; 3: 52. DOI: 10.1186/s41927–019–0094–3.

21. Ghosh S, Gensler LS, Yang Z, et al. Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs. Drug Saf. 2019 Jun; 42 (6): 751–768. DOI: 10.1007/s40264–019–00797–3.

22. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis – results of two phase 3 trials. N Engl J Med 2014; 371: 326–38. DOI: 10.1056/NEJMoa1314258.

23. McInnes IB, Mease PJ, Kirkham B. et al. Secukinumab, a human anti-interleukin 17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015 Sep 19; 386 (9999): 1137–46. DOI: 10.1016/S0140–6736(15)61134–5.

24. Saunte DM, Mrowietz U, Puig L, Zachariae C. Candida infections in psoriasis and psoriatic arthritis patients treated with IL 17 inhibitors and their practical management. Br J Dermatol. 2017 Jul; 177 (1): 47–62. DOI: 10.1111/bjd.15015.

25. Deodhar A, Mease PJ, McInnes IB, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther. 2019 May 2; 21 (1): 111. DOI: 10.1186/s13075–019–1882–2.

26. Препарат Талстм (иксекизумаб) компании «Лилли» зарегистрирован в РФ для лечения пациентов с активным псориатическим артритом. Современная ревматология. 2019; 13 (4): 148.

27. Combe B, Rahman P, Kameda H, et al. Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis. Arthritis Res Ther. 2020 Jan 21; 22 (1): 14. DOI: 10.1186/s13075–020–2099–0.

28. Mease PJ, Smolen JS, Behrens F, et al. A head-tohead comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2020 Jan; 79 (1): 123–131. DOI: 10.1136/annrheumdis2019–215386.

29. Burmester GR, Curtis JR, Yun H, et al. An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data. Drug Saf. 2020 Jan 31. DOI: 10.1007/s40264–020–00904–9.

30. Haber SL, Hamilton S, Bank M, et al. Apremilast: a novel drug for treatment of psoriasis and psoriatic arthritis. Ann Pharmacother 2016; 50 (4): 282–90. DOI: 10.1177/1060028015627467.

31. Keating GM. Apremilast: A Review in Psoriasis and Psoriatic Arthritis. Drugs. 2017 Mar; 77 (4): 459–472. DOI: 10.1007/s40265–017–0709–1.

32. Hagberg KW, Persson R, Vasilakis-Scaramozza C, et al. Herpes Zoster, Hepatitis C, and Tuberculosis Risk with Apremilast Compared to Biologics, DMARDs and Corticosteroids to Treat Psoriasis and Psoriatic Arthritis. Clin Epidemiol. 2020 Feb 12; 12: 153–161. DOI: 10.2147/CLEP.S239511.

33. de Vries MK, Arkema EV, Jonsson J, et al. Tuberculosis Risk in Ankylosing Spondylitis, Other Spondyloarthritis, and Psoriatic Arthritis in Sweden: A Population-Based Cohort Study. Arthritis Care Res (Hoboken). 2018 Oct; 70 (10): 1563–1567. DOI: 10.1002/acr.23487.

34. Aydin V, Akici A, Isli F, Relative risk of tuberculosis in patients with rheumatic diseases managed with anti-tumour necrosis factor-alpha therapy: A nationwide cohort study. J Clin Pharm Ther. 2019 Aug; 44 (4): 553–560. DOI: 10.1111/jcpt.12814.

35. Lynch M, Roche L, Horgan M, et al. Peritoneal tuberculosis in the setting of ustekinumab treatment for psoriasis. JAAD Case Rep. 2017 Apr 14; 3 (3): 230–232. DOI: 10.1016/j.jdcr.2017.02.001.

36. Tsai TF, Ho JC, Song M, et al. Efficacy and safety of ustekinumab for the treatment of moderate-to-severepsoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci. 2011 Sep; 63 (3): 154–63. DOI: 10.1016/j.jdermsci.2011.05.005.

37. Verstockt B, Deleenheer B, Van Assche G, et al. A safety assessment of biological therapies targeting the IL 23/IL 17 axis in inflammatory bowel diseases. Expert Opin Drug Saf. 2017 Jul; 16 (7): 809–821. DOI: 10.1080/14740338.2017.1338273.

38. Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. 2016; 375: 1946–60. DOI: 10.1056/NEJMoa1602773.

39. Braun J, Baraliakos X, Deodhar A, et al. Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE1 study. Rheumatology (Oxford). 2019 May 1; 58 (5): 859–868.

40. Лукина Г.В., Борисов С.Е. Скрининг и мониторинг туберкулезной инфекции у больных ревматическими заболеваниями, получающими генноинженерные биологические препараты. В кн. Российские рекомендации. Ревматология. Под ред. Е. Л. Насонова. М., ГЭОТАР-Медиа, 2017. С. 394–410.

41. Snast I, Atzmony L, Braun M, et al. Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature. J Am Acad Dermatol. 2017 Jul; 77 (1): 88–97. e5. DOI: 10.1016/j.jaad.2017.01.037.

42. Amin M, No DJ, Egeberg A, Wu JJ. Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say? Am J Clin Dermatol. 2018 Feb; 19 (1): 1–13. DOI: 10.1007/s40257–017–0328–3.

43. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C2018. J Hepatol. 2018 Aug; 69 (2): 461–511. DOI: 10.1016/j.jhep.2018.03.026.

44. Sebastiani M, Milazzo L, Atzeni F, et al. Italian consensus recommendations for the management of hepatitis C infection in patients with rheumatoid arthritis. Mod Rheumatol. 2019 Jan 22: 1–8. DOI: 10.1080/14397595.2018.1558918.

45. Winthrop KL, Yamanaka H, Valdez H, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014 Oct; 66 (10): 2675–84. DOI: 10.1002/art.38745.

46. Winthrop KL, Lebwohl M, Cohen AD, et al. Herpes zoster in psoriasis patients treated with tofacitinib. J Am Acad Dermatol. 2017 Aug; 77 (2): 302–309. DOI: 10.1016/j.jaad.2017.03.023.

47. Atzeni F, Talotta R, Nucera V, et al. Adverse events, clinical considerations and management recommendations in rheumatoid arthritis patients treated with JAK inhibitors. Expert Rev Clin Immunol. 2018; 14 (11): 945–956. DOI: 10.1080/1744666X.2018.1504678.

48. Almanzar G, Kienle F, Schmalzing M, et al. Tofacitinib modulates the VZV-specific CD4 + T cell immune response in vitro in lymphocytes of patients with rheumatoid arthritis. Rheumatology. 2019 May 18. DOI: 10.1093/rheumatology/kez175.

49. Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020 Jan; 79 (1): 39–52. DOI: 10.1136/annrheumdis2019–215882.

50. Baumrin E, Van Voorhees A, Garg A, et al. A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2019 Jul; 81 (1): 102–110. DOI: 10.1016/j.jaad.2019.03.017.


Для цитирования:


Белов Б.С., Муравьева Н.В., Баранова М.М., Коротаева Т.В. Проблема коморбидных инфекций у больных псориатическим артритом. Медицинский алфавит. 2020;(15 (2020)):22-28. https://doi.org/10.33667/2078-5631-2020-15-22-28

For citation:


Belov B.S., Muravyova N.V., Baranova M.M., Korotaeva T.V. Problem of comorbid infections in patients with psoriatic arthritis. Medical alphabet. 2020;(15 (2020)):22-28. (In Russ.) https://doi.org/10.33667/2078-5631-2020-15-22-28

Просмотров: 26


ISSN 2078-5631 (Print)